



Elsevier Life Science Solution

加速药物研发决策

吴鹏 17321403735

p.wu.1@elsevier.com

爱思唯尔生命科学客户顾问



内容

➤ Elsevier 生命科学解决方案

1. Reaxys对信息的提炼介绍，以及信息检索基础技巧
2. Reaxys专利检索策略
3. RMC辅助药物分子设计研发决策
4. PharmaPendium辅助药物临床研究

➤ 总结


从数据库性质出发的分类方法



1. 注重速度
2. 数据整合
3. 缺乏系统化索引
4. 起到“告知”作用



1. 注重宏观面
2. 更新速度慢
3. 参考作用
4. 定位“全局”作用



1. 主要支持研发
2. 主要来源期刊，专利
3. 完善的索引体系
4. 解决“为什么”，“怎么做”，“做什么”的问题

Reaxys对这篇文献的索引—Key Word和题录摘要

Assessment of the regioselectivity in the condensation reaction of unsymmetrical o-phthalaldehydes with alanine¹

[D'Hollander, Agathe C.A.; Westwood, Nicholas J.](#) - [Tetrahedron, 2018, vol. 74, # 2, p. 224 - 239]

[Abstract](#) ^ [Index Terms](#) ^ [Substances](#) 103 v [Reactions](#) 236 v [Full Text](#) ↗

Abstract

One approach for the synthesis of isoindolinones, a privileged bioactive heterocyclic core structure, involves a condensation reaction of o-phthalaldehydes with a suitable nitrogen-containing nucleophile. This fascinating reaction is revisited here in the context of the use of o-phthalaldehydes that contain additional substituents in the aromatic ring leading to a detailed analysis of the regioselectivity of the reaction. Eleven monosubstituted o-phthalaldehydes were synthesised and reacted with alanine. The regioselectivity observed across the eleven substrates led to the design of a disubstituted substrate that reacted with very high control. A gram-scale reaction followed by esterification gave one major regioisomer in high yield. In addition, the regioselectivity observed on reaction of two novel monodeuterated substrates led to an increased mechanistic understanding.

Index terms

Author keyword: Condensation reaction, Mechanistic understanding, o-phthalaldehyde, Regioselectivity

EMTREE drug term: alanine, phthalaldehyde

EMTREE medical term: Article, esterification, polymerization, priority journal, regioselectivity, synthesis

Reaxys Index Terms: Swern oxidation, condensation reaction, esterification, pure, reactivity, regioselectivity, separation method, tautomerization




关键内容的提炼源自Elsevier不同的资源，Embase中的一级索引，EI索引，作者关键词，Reaxys自己的词库

Reaxys对这篇文献的索引—物质与反应

Assessment of the regioselectivity in the condensation reaction of unsymmetrical o-phthalaldehydes
1 with alanine
[D'Hollander, Agathe C.A.; Westwood, Nicholas J.](#) - [Tetrahedron, 2018, vol. 74, # 2, p. 224 - 239]
[Abstract](#) ▾ [Index Terms](#) ▾ [Substances](#) 103 ▾ [Reactions](#) 236 ▾ [Full Text](#) ↗

对于原文中出现的化合物21a，Reaxys都提取了什么信息



Reaxys对文献中的化合物的深度提炼



2-(6-methoxy-1-oxoisindolin-2-yl)propanoic acid
C₁₂H₁₃NO₄ 235.24 32021463

Hit Data - 7
Identification
Druglikeness

Physical Data - 2
Spectra - 4
Preparations - 7 >
Reactions - 7 >
Documents - 1 >

Hit Data - 7

- Substance Label - 1 hits out of 1
- Melting Point - 1 hits out of 1
- Crystal Property Description - 1 hits out of 1
- NMR Spectroscopy - 2 hits out of 2
- IR Spectroscopy - 1 hits out of 1
- Mass Spectrometry - 1 hits out of 1

Hit Data:
在这篇文献中出现的和21a有关的重要数据

Reaxys的深度提炼内容

^ Hit Data - 7

- ✓ Substance Label - 1 hits out of 1
- ✓ Melting Point - 1 hits out of 1
- ✓ Crystal Property Description - 1 hits out of 1
- ✓ NMR Spectroscopy - 2 hits out of 2
- ✓ IR Spectroscopy - 1 hits out of 1
- ✓ Mass Spectrometry - 1 hits out of 1

Reaxys重点提炼的是文献中的关键数据。

Label	Reference
21a	D'Hollander, Agathe C.A.; Westwood, Nicholas J. - [Tetrahedron, 2018, vol. 74, # 2, p. 224 - 239] Full Text ↗ Details > Abstract >

Melting Point, °C	Reference
194 - 196	D'Hollander, Agathe C.A.; Westwood, Nicholas J. - [Tetrahedron, 2018, vol. 74, # 2, p. 224 - 239] Full Text ↗ Details > Abstract >

Colour & Other Properties	Location	Reference
white	supporting information	D'Hollander, Agathe C.A.; Westwood, Nicholas J. - [Tetrahedron, 2018, vol. 74, # 2, p. 224 - 239] Full Text ↗ Details > Abstract >

Description (NMR Spectroscopy)	Nucleus (NMR Spectroscopy)	Solvents (NMR Spectroscopy)	Frequency (NMR Spectroscopy), MHz	Location	Reference
Chemical shifts, Spectrum	¹ H	d(4)-methanol	500	supporting information	D'Hollander, Agathe C.A.; Westwood, Nicholas J. - [Tetrahedron, 2018, vol. 74, # 2, p. 224 - 239] Full Text ↗ Details > Abstract >
Chemical shifts, Spectrum	¹³ C	d(4)-methanol	125.8	supporting information	D'Hollander, Agathe C.A.; Westwood, Nicholas J. - [Tetrahedron, 2018, vol. 74, # 2, p. 224 - 239] Full Text ↗ Details > Abstract >

Reaxys对原文反应的提炼 (21a)

Reaction ID: 47133770

The reaction scheme shows the synthesis of two regioisomers, 21a and 22a, from alanine and 4-methoxyphthalaldehyde. Alanine (16) reacts with 4-methoxyphthalaldehyde (20a) to produce a mixture of 21a and 22a. The reaction is regioselective, yielding 38 mg of a mixture of regioisomers.

1 Conditions [Find Similar](#)

Yield	Conditions	Reference
In acetonitrile for 4h; Reflux; Inert atmosphere; Overall yield = 90 percent; Overall yield = 38 mg; regioselective reaction;	Experimental Procedure	D'Hollander, Agathe C.A.; Westwood, Nicholas J. - [Tetrahedron, 2018, vol. 74, # 2, p. 224 - 239] Full Text Details Abstract

General procedure: Alanine (16, 1.2 equiv.) was added to a solution of unsymmetrical o-phthalaldehyde (1.0 equiv.) in anhydrous MeCN (3.8 mL per mmol of o-phthalaldehyde). The reaction mixture was heated at reflux for 4 h under a nitrogen atmosphere. The solution was then cooled to rt before being concentrated in vacuo to afford the crude mixture of regioisomers.

原文中的General Procedure会被替换成对应的内容

4.3.9. 2-(6-Methoxy-1-oxoisoindolin-2-yl)propanoic acid (**21a**) with 2-(5-methoxy-1-oxoisoindolin-2-yl)propanoic acid (**22a**)
A mixture of **21a** and **22a** was synthesised according to general procedure **B** using 4-methoxyphthalaldehyde (**20a**, 1.0 equiv., 30 mg, 0.18 mmol) and alanine (**16**, 1.2 equiv., 19 mg, 0.22 mmol). A

Reaxys数据库对专利信息的提炼

专利中的实施例结构，反应，靶点

快速处理专利的生物活性数据

1 Documents with 196 Substances, 397 Reactions, 1 Targets

0 selected Limit To Exclude Export

Sort by Publication Year ↓

Heatmap

HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS

1 Incyte Corporation; Wu, Liangxing; Qian, Ding-Quan; Lu, Liang; Lajkiewicz, Neil; Konkol, Leah C.; Li, Zhenwu; (...) Xiao, Kaijiong; Yao, Wenqing
US2018/177784, 2018, A1
Patent Family Members: TW2018/35073 A; US2018/177784 A1; US2018/177870 A1; US2018/179179 A1; US2018/179197 A1; ...

Abstract Claims Front Page Info Substances 196 Reactions 397 Targets Full Text

专利中的发明描述


专利标记信息：族号，专利分类，公开日期等

原文链接

Reaxys对这篇专利的提炼—实施例结构（其中一个实施例）

63 Substances out of 1 Documents, containing 15 Reactions, 4 Targets

0 selected [Limit To](#) [Exclude](#) [Export](#) [Sort by No of References](#) [Heatmap](#)

16  **1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one**
C₂₅H₂₄N₆O₂ 440.505 13102237

[Hit Data - 5](#) [Druglikeness](#) [Physical Data - 4](#) [Preparations - 7](#)
[Identification](#) [Bioactivity \(All\)](#) [Spectra - 6](#) [Reactions - 8](#)
[Targets - 37](#)
[Documents - 34](#)

[Hit Data - 5](#)

- Substance Label - 1 hits out of 5
- Patent-Specific Data - 1 hits out of 4
- Crystal Property Description - 1 hits out of 3
- NMR Spectroscopy - 1 hits out of 3
- Mass Spectrometry - 1 hits out of 3

1. 物质在该专利中的标记
2. 物质在该专利中的特殊的数据（Markush相关）
3. 物质的晶体描述
4. 物质在该专利中的NMR数据
5. 物质在该专利中的Mass数据

Reaxys对这篇专利的提炼—实施例细节

Hit Data - 5

- Substance Label - 1 hits out of 5
- Patent-Specific Data - 1 hits out of 4
- Crystal Property Description - 1 hits out of 3**
- NMR Spectroscopy - 1 hits out of 3
- Mass Spectrometry - 1 hits out of 3

Label	Reference
Compound 4	PHARMACYCLICS, INC. - US2008/76921 , 2008, A1 Full Text Details Abstract
	Pharmacyclics LLC; Buggy, Joseph J.; Elias, Laurence; Fyfe, Gwe Full Text Details Abstract

Related Markush Structure (RN)	Reference
13109621	PHARMACYCLICS, INC. - US2008/76921 Full Text Details Abstract

Colour & Other Properties	Reference
white	PHARMACYCLICS, INC. - US2008/76921 , Full Text Details Abstract

NMR Spectroscopy - 1 hits out of 3

Nucleus (NMR Spectroscopy)	Frequency (NMR Spectroscopy), MHz	Original Text (NMR Spectroscopy)	Comment (NMR Spectroscopy)	Signals, ppm	Reference
¹ H	400	¹ H-NMR (400 MHz): 8.26, s, 1H; 7.65, m, 2H; 7.42, m, 2H; 7.1-7.2, m, 5H; 6.7-6.9, m, 1H; 6.1, m, 1H; 5.5-5.7, n, 1H; 4.7, m, 1H; 4.54, m, 0.5H; 4.2, m, 1H; 4.1, n, 0.5H; 3.7, nm, 0.5H; 3.2, m, 1H; 3.0, m, 0.5H; 2.3, m, 1H; 2.1, m, 1H; 1.9, m, 1H; 1.6, m, 1H	Signals given	8.26	PHARMACYCLICS, INC. - US2008/76921 , 2008, A1 Full Text Details Abstract


Tips:

1. 利用物质标识，可以直接在专利全文中直接定位物质在专利中的位置。
2. Related Markush，直接给出实施例被保护的Markush结构
3. 晶体描述，核磁，质谱数据的直接给出

Reaxys对这篇专利的提炼—Markush结构

1 Substances out of 1 Documents, containing 0 Reactions, 0 Targets

0 No of References ↓

1  **Reaxys ID: 13109621**
13109621

[Hit Data - 195](#) Documents - 1 >

Identification

[Other Data - 193](#)

Markush结构的具体描述

^ Hit Data - 195

- Substance Label - 1 hits out of 1
- Patent-Specific Data - 1 hits out of 1
- Use - 193 hits out of 193

1. Markush结构在该专利中的标记
2. Markush结构该专利中的位置
3. Markush结构涉及的应用

内容

➤ Elsevier 生命科学解决方案

1. Reaxys对信息的提炼介绍，以及信息检索基础技巧
2. Reaxys专利检索策略
3. RMC辅助药物分子设计研发决策
4. PharmaPendium辅助药物临床研究

➤ 总结

Reaxys检索方法总览

Reaxys[®] Quick search Query builder Results Synthesis planner History

Search for [Icon] Import

Search Reaxys

Substance CAS Registry Number, e.g. 102625-70-7

AND

Find >

Feedback

结构式索引化合物信息

Reaxys[®] Quick search Query builder Results Synthesis planner History

Search in: Reactions > Targets > Substances > Documents >

Import Save Reset form Delete all

Structure Molecular Formula CAS RN Doc. Index

Document Basic Index is Document Basic Index

AND Patent Assignee is Patent Assignee

AND Patents: Main IPC is Main IPC

AND Patents: Date of publ... is

Find >

Feedback

综合信息的自定义模块化组合检索

Reaxys[®] Quick search Query builder Results Synthesis planner History

Search for [Icon] Import

Search Reaxys

Substance Molecular Formula, e.g. Pt(PPh₃)₃

AND

Find >

Feedback

结构式索引反应信息

Reaxys[®] Quick search Query builder Results Synthesis planner History

Search in: Reactions > Targets > Substances > Documents >

Import Save Reset form Delete all

Structure Molecular Formula CAS RN Doc. Index

Caco-2 permeability

Structure

Create Structure / Reaction Drawing

AND Cells/Cell Lines is 'Caco-2 cell line';Caco-2

AND Measurement Parameter is

Find >

Feedback

特殊信息的预设模块化组合检索

Reaxys结果集筛选方法总览

Reaxys Quick search Query builder Results Synthesis planner His

37,826 Reactions out of 12,016 Documents containing 37,880 Substances, 2,832 Targets

0 selected Limit To Exclude Export Syn-Plan

1

15 Conditions Find Similar Reaction ID: 2066982

Conditions

With sodium min;

With diisobut

37.83 K

Filters

Limit to > Exclude >

By Structure >

Yield >

Reagent/Catalyst >

Solvent >

Catalyst Classes >

Solvent Classes >

Product Availability >

Reactant Availability >

Reaction Classes >

Document Type >

Publication Year >

Single step reactions only

Reagent/Catalyst

- lithium aluminium tetr... 17,292
- potassium carbonate 5,997
- diisobutylaluminium hyd... 4,406
- sodium tetrahydroborate 4,142
- triethylamine 4,112
- hydrogen 3,822
- hydrogenchloride 3,314

Filter by value > View more

Filters

Limit to > Exclude >

By Structure >

Draw

As drawn

Catalyst Classes

Catalyst Classes

- active center 32,458
 - Al 22,400
 - B 10,432
 - Pd 5,658
 - Cu 2,079
 - Fe 1,327
 - Zn 1,050
 - Sn 711
 - Ag 387

Clear selected x Limit to > Exclude >

Substance Classes 213

- Substance Classes 37,880
- Functional Group Classification 36,399
- Ring Classification 36,101
 - 6-membered rings 36,042
 - 9-18-membered rings 13,282
 - 5-membered rings 9,221
 - 3-membered rings 780
 - cyclopropane and derivatives 529
 - cyclopropylcyclohexane and heteroatomic analogs 334
 - cyclopropylbenzene and derivatives 213
 - cyclopropylcyclohexane and heteroatomic analogs - not further classified 76

Selected search items:

cyclopropylbe... ivatives x

Clear selected x Limit

Index Terms (List)

Clear selected x Sort by Occurrence >

- cyclization reaction 486
- oxidation reaction 469
- total synthesis 427
- catalyst 410
- catalytic reaction 389
- reactivity 312
- alkylation 294
- ic50 292
- hydrogenation 290
- crystal structure 274

1 2 3 ... 69 Go to page > Limit to > Exclude >

Document Type >

- article 7,168
- patent 4,768
- conference paper 26
- article in press 21
- review 18
- letter 11
- retracted article 1

View more



Case 1 化合物衍生物检索及其分析

- 检索以下列母核为基础的衍生化合物信息
- 快速获取其特定信息，核磁图谱，溶解度信息等
- 快速分析衍生物的大致结构式构成
- 快速获取某个特定结构的合成路线

The screenshot displays the Reaxys software interface. The main window shows a chemical structure editor with a benzimidazole derivative (2-aminobenzimidazole) drawn in blue. The interface includes a top navigation bar with 'Quick search', 'Query builder', 'Results', 'Synthesis planner', and 'History'. Below the navigation bar, there are tabs for 'Structure editor' and 'ChemAxon's MarvinJS'. A search bar at the top right contains the text 'Search this structure as:'. The search options are: 'As drawn' (radio button), 'As substructure' (radio button, selected), 'On all atoms' (radio button, selected), 'On heteroatoms' (radio button), and 'Similar' (radio button). Below these options, there are several checkboxes: 'Tautomers' (unchecked), 'Stereo' (checked), 'Additional ring closures' (checked), 'Related Markush' (unchecked), 'Salts' (checked), 'Mixtures' (checked), 'Isotopes' (checked), 'Charges' (checked), and 'Radicals' (checked). At the bottom of the interface, there are buttons for 'Clear', 'Cancel', and 'Transfer to query'. A 'Feedback' button is located in the bottom right corner.

亚结构检索功能
扩展所画结构为
相关衍生物

这些选项却保，
把相关的异构体
也检索出来

Case 1 化合物衍生物检索结果

96,884 K

Filters

Limit to > Exclude >

By Structure >

Measurement pX >

Highest Clinical Phases >

Targets >

Parameters >

Substance Classes >

96,884 Substances out of 21,106 Documents, containing 148,635 Reactions, 4,242 Targets


Reaxys - 96,884

0 selected Limit To Exclude Export

Sort by No of References ↓

Grid Heatmap

1



gefitinib
C₂₂H₂₄N₄ClFO₃ 446.909 8949523 184475-35-2

Identification	Bioactivity (All)	Spectra - 65	Preparations - 76 >
Druglikeness	Physical Data - 88	Other Data - 2,966	Reactions - 116 >
			Targets - 1,069 >
			Documents - 6,102 >

^ Spectra - 65

- ✓ NMR Spectroscopy - 38
- ✓ IR Spectroscopy - 9
- ✓ Mass Spectrometry - 12
- ✓ UV/VIS Spectroscopy - 5
- ✓ Raman Spectroscopy - 1

^ Physical Data - 88

- ✓ Melting Point - 25
- ✓ Association (MCS) - 5
- ✓ Chromatographic Data - 5
- ✓ Conformation - 1
- ✓ Crystal Phase - 7

^ Bioactivity (All)

- ✓ In vitro: Efficacy - 4878
- ✓ In vivo: Animal Model - 627
- ✓ Metabolism - 311
- ✓ Pharmacokinetic - 672
- ✓ Toxicity/Safety Pharmacology - 1393

Case 1 化合物衍生物检索结果

^ Spectra - 65
✓ NMR Spectroscopy - 38
✓ IR Spectroscopy - 9
✓ Mass Spectrometry - 12
✓ UV/VIS Spectroscopy - 5
✓ Raman Spectroscopy - 1

Description (NMR Spectroscopy)	Nucleus (NMR Spectroscopy)	Coupling Nuclei	Solvents (NMR Spectroscopy)	Temperature (NMR Spectroscopy), °C	Frequency (NMR Spectroscopy), MHz	Original Text (NMR Spectroscopy)	Location	Comment (NMR Spectroscopy)	Signals, ppm	Kind of signal	Reference
Chemical shifts	¹ H		dimethylsulfoxide-d ₆		300		Paragraph 0096				Mingmin Full Text
Chemical shifts	¹³ C		dimethylsulfoxide-d ₆		75		Paragraph 0096				Shaanxi Wang, Liu WeiCN10 Full Text
Chemical shifts	¹ H		dimethylsulfoxide-d ₆		400	<p>1H NMR (400 MHz, d₆-DMSO) δ 9.44 (s, 1H), 8.50 (s, 1H), 8.12 (dd, J = 6.9, 2.7 Hz, 1H), 7.80 (m, 2H), 7.44 (t, 1H), 7.20 (s, 1H), 4.18 (t, J = 6.7 Hz, 2H), 3.94 (s, 3H), 3.59 (t, J = 4.4 Hz, 4H), 2.49 (t, J = 6.9 Hz, 2H), 2.41 (bs, 4H), 2.00 (m, 2H).</p>	Paragraph 0035				SCINOP-LTD.; ZH, 2015, A1 Full Text
Chemical shifts	¹³ C		dimethylsulfoxide-d ₆		100	<p>13C NMR (100 MHz, d₆-DMSO) δ 156.48, 154.94, 153.57 (J = 241 Hz), 153.05, 148.74, 147.43, 137.33 (J = 3 Hz), 123.01, 122.77 (J = 7 Hz), 119.19 (J = 19 Hz), 116.90 (J = 21 Hz), 77.59, 66.43, 56.31, 55.35, 53.73, 26.13.</p>	Paragraph 0035				SCINOP-LTD.; ZH, 2015, A1 Full Text

正文中位置

正文中具体数据

原文链接

Case 1 化合物合成路线

1

购物车 合成路线

Shopping cart icon:

Synthesis route icon:

Synthesize ×

> Manually 手动

> **Autoplan** 自动

自动设计合成了路线参数设置

Substance Availability ×

- Accelrys' ACD
- CambridgeSoft ACX
- Labnetwork
- PharmaPendium
- Sigma Aldrich
- ^{5g}_{\$100} eMolecules

国内供应商

国际供应商

Create plans by autoplan ×

Number of plans to create ∨ 合成计划数

Max. alternative branches ∨ 每个计划中每步分支

Max. number of steps ∨ 每个计划中多少步合成目标


Stop searching if starting material is commercially available Yes No 当原料可购买时，是否停止设计

Default yield for reactions without a given yield 每步收率

Always show screen before creating autoplan

[Create Plans >](#)

Case 1 化合物合成路线



Case 1 衍生物结构式类型快速分析

Filters

96,884 Substances out of 21,106 Documents, containing 148,6

Limit to > Exclude >

By Structure >

Measurement pX >

Highest Clinical Phases >

Targets >

Parameters >

Substance Classes >

Molecular Weight >

Number of Fragments >

Availability >

Availability in other databases >

Available Data >

0 Limit To Exclude Export

1

2

Substance Classes

Substance Classes	96,884
Functional Group Classification	90,750
Richter Classification	90,747
Ring Classification	90,747
6-membered rings	90,743
9-18-membered rings	90,722
5-membered rings	35,143
3-membered rings	
4-membered rings	
7-membered rings	
8-membered rings	

按官能团种类分
按官芳香性种类分
按官环结构种类分

3-membered rings

- cyclopropane and derivatives
- (2-cyclopropylethyl)cyclohexane and heteroatomic analogs
 - (cyclopropylmethoxy)benzene and derivatives
 - N-benzylcyclopropanamine and derivatives
 - N-(biphenyl-3-ylmethyl)cyclopropanamine and derivatives
 - 7-(cyclopropylmethoxy)-N-phenylquinazolin-4-amine and derivatives
 - N-cyclopropyl-6-[3-[(cyclopropylamino)methyl]phenyl]quinazolin-4-amine and derivatives

Clear selected X


Case 1 衍生物结构式类型快速分析


455 Substances out of 112 Documents, containing 346 Reactions, 52 Targets


Reaxys - 455


0 Limit To Exclude Export


No of References ↓ List Heatmap


1 


2 


3 


4 


5 

6 

7 

8 


9 

10 

Feedback

Case 2 同机理化学反应条件的检索

- 参与反应结构太复杂；结构太新颖。如何用同机理的反应条件检索知道实验？
- 如何快速分型最常用试剂？
- 如何快速获取特定催化剂？



Case 2 同机理化学反应条件的检索

The screenshot displays the ChemAxon's MarvinJS structure editor interface. The main workspace shows a chemical reaction: benzaldehyde (left) reacts to form benzyl alcohol (right). The carbonyl carbon in benzaldehyde is highlighted with a red circle and labeled "对应反应前后反应位点" (Corresponding reaction site before and after the reaction). The hydroxyl hydrogen in benzyl alcohol is highlighted with a red circle and labeled "锁定该原子上只能是H" (Lock this atom, it can only be H). The search options panel on the right is open, with "As substructure" selected. The "On all atoms" sub-option is also selected. The "Similar" option is also selected. The "Transfer to query" button is visible at the bottom right.

Structure editor ChemAxon's MarvinJS

Create structure template from name >

Search this structure as:

- As drawn
- As substructure
 - On all atoms
 - On heteroatoms
- Similar

亚结构检索扩展为机理相同反应

对应反应前后反应位点

锁定该原子上只能是H

1-1

Clear Cancel Transfer to query >

+ More options Feedback

Case 2 结果集的快速筛选

快速获取最常用试剂条件

快速获取特定试剂条件

The screenshot displays a chemical reaction database interface. On the left, a 'Filters' sidebar shows 13,744 results. The 'Reagent/Catalyst' and 'Catalyst Classes' filters are highlighted with orange boxes and arrows pointing to the text above. The main area shows 13,741 reactions out of 8,734 documents. A chemical reaction is shown: 4-bromobenzaldehyde reacts to form 4-bromobenzyl alcohol. Below the reaction, there are icons for shopping cart, zoom, and other actions. A table below the reaction provides conditions, yield, and reference information.

13,741 Reactions out of 8,734 Documents containing 20,523 Substances, 1,622 Targets

Limit To Exclude Export Syn-Plan

Reagent/Catalyst

Catalyst Classes

15 Conditions Find Similar Reaction ID: 2066982

Conditions	Yield	Reference
With sodium bis(2-methoxyethoxy)aluminium dihydride In toluene 1.) 10-20 deg C, 2.) room temperature, 10 min;	100%	Wells, Andy [Synthetic Communications, 1996, vol. 26, # 6, p. 1143 - 1147] Full Text Cited 1 times Details Abstract

Case 2 常用试剂条件获取

Reagent/Catalyst ^

- lithium aluminium tetrah... 7,535
- diisobutylaluminium hyd... 1,664
- sodium tetrahydroborate 1,519
- water 1,345
- hydrogenchloride 1,007
- borane-thf 1,003
- sodium hydroxide 884

Filter by value v [View more](#)

把数万条操作步骤中的试剂，按使用频繁度排序

Reagent/Catalyst Clear selected x ↓ ↑ Sort by Occurrence v x

<input type="checkbox"/> lithium aluminium tetrahydride	7,535
<input type="checkbox"/> diisobutylaluminium hydride	1,664
<input type="checkbox"/> sodium tetrahydroborate	1,519
<input type="checkbox"/> water	1,345
<input type="checkbox"/> hydrogenchloride	1,007
<input type="checkbox"/> borane-thf	1,003
<input type="checkbox"/> sodium hydroxide	884
<input type="checkbox"/> potassium carbonate	883
<input type="checkbox"/> lithium borohydride	869
<input type="checkbox"/> sulfuric acid	668

1 2 3 ... 36 > Go to page > Limit to > Exclude >

Case 2 特定试剂条件获取

Catalyst Classes

- active center 12,989
- heterogeneous 247
- organism / enzymes 9

[View more](#)

Catalyst Classes

▼ Catalyst Classes		13,741
> active center	有催化中心试剂	12,989
> heterogeneous	无催化中心试剂	247
> organism / enzymes	生物催化试剂	9

Catalyst Classes 1003

▼ Catalyst Classes		13,741
▼ active center		12,989
> AI		9,482
▼ B		4,086
<input type="checkbox"/> sodium tetrahydroborate		1,519
<input checked="" type="checkbox"/> borane-THF		1,003
<input type="checkbox"/> lithium borohydride		847
<input type="checkbox"/> dimethylsulfide borane complex		442
<input type="checkbox"/> boron trifluoride diethyl etherate		228
<input type="checkbox"/> borane		225

Case 2 特定试剂条件获取

1,003 Reactions out of 1,745 Documents containing 1,645 Substances, 199 Targets

Limit To Exclude Export Syn-Plan Reaxys Ranking

1

通过试剂筛选，可以把特定条件，从所有报道过的条件中挑选出来

2 Hits ^ 6 Conditions v Find Similar > Reaction ID: 9591163

Conditions	Yield	Reference
With borane-THF In tetrahydrofuran at 0 - 20°C; Experimental Procedure v	94%	Jankowiak, Aleksandra; Obijalska, Emilia; Kaszynski, Piotr [Beilstein Journal of Organic Chemistry, 2013, vol. 9, p. 1873 - 1880] Full Text ^ Cited 5 times ^ Details > Abstract >

Feedback

内容

➤ Elsevier 生命科学解决方案

1. Reaxys对信息的提炼介绍，以及信息检索基础技巧
2. Reaxys专利检索策略
3. RMC辅助药物分子设计研发决策
4. PharmaPendium辅助药物临床研究

➤ 总结

Reaxys中专利收录情况

Patent Offices	Time they cover	Indexed content
Various	1803 - 1980	<ul style="list-style-type: none">•Substance and reaction data•Patent citation information•Most organic chemistry
English language patents from World, US, and European patent offices.	1976 - 2001 (automatic) 2001 - present (manual)	Includes the content above and: <ul style="list-style-type: none">•Markush substance display•All patent family members•Classification codes
Asian patent offices in original language with English abstracts (China, Taiwan, South Korea, Japan)	2015 - present (manual: JP, KR) 2016 - present (manual: CN, TW)	Includes the same content as for WO, US and EP patent offices

1. 2015年以前，只有JP,KR的专利，没有申请WO, US,EP，则不被收录
2. 2016年以前，只有CN,TW的专利，没有申请WO, US, EP,则不被收录
3. 2015年以前，JP,KR；2016年以前CN,TW；具有WO,但是不具有英文版本，则不会摘录具体数据

- Reaxys中专利数据的抓取数据（2019年开始）
 - 专利公布，（通常3-10日，由专利局控制）获得专利局传递的数据
 - 文字内容：标题，摘要，claim，专利标记，授权人，发明人等，最迟10天内抓取入数据库
 - 化合物结构：包含名称结构的翻译，最迟1-1.5月内抓取入数据库（内容量影响抓取数据）
 - 生物活性数据等：最迟2月-2.5月内抓取入数据库（内容量影响抓取数据）

常用的综合检索专利的模块等

◇ Structure ✕

 Create Structure / Reaction Drawing

结构式

◇ Document Basic Index is ▼ Document Basic Index 🔍 ✕

关键词索引,
可索引专利
claim

◇ Patent Assignee is ▼ Patent Assignee 🔍 ✕

专利授权人

◇ Common Patent Number is ▼ Common Patent Number 🔍 ✕

通用专利号

◇ Patents: Main IPC is ▼ Main IPC 🔍 ✕

1级IPC

◇ Patents: Secondary IPC is ▼ Secondary IPC 🔍 ✕

2级IPC

◇ Patents: Date of publ... is ▼ Date of publication 🔍 ✕

公开日期（不分专
利类型A或B，以最
近的进行日期进行匹配）

Case 3: 检索‘辉瑞’为授权者，并具有某‘特定结构专利’

The screenshot displays a chemical search interface. At the top, there are search filters for 'Reactions', 'Targets', 'Substances', and 'Documents'. Below these are icons for 'Import', 'Save', 'Reset form', and 'Delete all'. On the right, there are icons for 'Structure', 'Molecular Formula', 'CAS RN', and 'Doc. Index'. The main search area is titled 'Structure' and contains a chemical structure of a benzimidazole derivative with an amino group (NH₂) attached to the imidazole ring. To the right of the structure, the text reads: '只需要结构式+授权人组合即可' (Only need structure + assigner combination). Below the structure, the text reads: '在指定授权人时，可以通尽可能过‘contain’逻辑来扩展授权人的‘全名’' (When specifying the assigner, you can use the 'contain' logic to expand the assigner's 'full name'). At the bottom, there is a search bar with the text 'Patent Assigner' and a dropdown menu showing search operators: 'contains', 'ends with', 'is', 'contains', and 'starts with'. The 'contains' operator is selected, and the search term 'pfizer' is entered. The 'AND' button is visible on the left.

Search in: Reactions > Targets > Substances > Documents >

Import Save Reset form Delete all

Structure Molecular Formula CAS RN Doc. Index

Structure

NH₂

只需要结构式+授权人组合即可

On all atoms

在指定授权人时，可以通尽可能过‘contain’逻辑来扩展授权人的‘全名’

AND

Patent Assigner

contains

ends with

is

contains

starts with

contains pfizer

ELSEVIER

设定条件都会去命中

112 Documents with 8,824 Substances, 7,789 Reactions, 59 Targets

0 selected Limit To Exclude Export Sort by Publication Year ↓ Heatmap

- SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS**
1 **PFIZER INC.**; KUMPF, ROBERT ARNOLD; MCALPINE, INDRAWAN JAMES; MCTIGUE, MICHELE ANN; PATMAN, RYAN; RUI, EUGENE YUANJIN; TATLOCK, JOHN HOWARD; TRAN-DUBE, MICHELLE BICH; WYTHES, MARTIN JAMES TW2018/2074, 2018, A
Patent Family Members: CA2969295 A1; US2017/348313 A1; WO2017/212385 A1; TW2018/2074 A; UY37274 A; ...
[Abstract](#) [Claims](#) [Front Page Info](#) [Substances 653](#) [Reactions 1611](#) [Full Text](#)
[Hit Substances 1](#)
- Antibodies to insulin-like growth factor I receptor**
2 **Pfizer Inc.**; Amgen Fremont Inc.; Cohen, Bruce D.; Beebe, Jr., Jean; Miller, Penelope E.; Moyer, James D.; Corvalan, Jose Ramon; Gallo, Michael US9234041, 2016, B2
Patent Family Members: HN2001000283 A; UY27087 A1; CA2433800 A1; DZ3494 A1; WO2002/53596 A2; ...
[Abstract](#) [Claims](#) [Front Page Info](#) [Substances 18](#) [Full Text](#)
[Hit Substances 1](#)
- Quinazoline derivatives**
3 **Pfizer Products Inc.**; OSI Pharmaceuticals, LLC; Schnur, Rodney Caughren; Arnold, Lee Daniel EP2163546, 2016, B1
Patent Family Members: NO961299 D0; HU9600834 D0; IL117598 D0; MA23831 A1; NO961299 A; ...
[Abstract](#) [Claims](#) [Front Page Info](#) [Substances 196](#) [Reactions 236](#) [Full Text](#)
[Hit Substances 129](#)

专利的信息摘取

□ SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

1 PFIZER INC.; KUMPF, ROBERT ARNOLD; MCALPINE, INDRAWAN JAMES; MCTIGUE, MICHELE ANN; PATMAN, RYAN; RUI, EUGENE YUANJIN; TATLOCK, JOHN HOWARD; TRAN-DUBE, MICHELLE BICH; WYTHES, MARTIN JAMES TW2018/2074, 2018, A

Patent Family Members: CA2969295 A1; US2017/348313 A1; WO2017/212385 A1; TW2018/2074 A; UY37274 A; ...

Abstract ▾ Claims ▾ Front Page Info ▾ Substances 653 ▾ Reactions 1611 ▾ Full Text ↗

Hit Substances 1 ▾

Assignees			Inventors (Authors)		
PFIZER INC.; KUMPF, ROBERT ARNOLD; MCALPINE, INDRAWAN JAMES; MCTIGUE, MICHELE ANN; PATMAN, RYAN; RUI, EUGENE YUANJIN; TATLOCK, JOHN HOWARD; TRAN-DUBE, MICHELLE BICH; WYTHES, MARTIN JAMES			KUMPF, ROBERT ARNOLD; MCALPINE, INDRAWAN JAMES; MCTIGUE, MICHELE ANN; PATMAN, RYAN; RUI, EUGENE YUANJIN; TATLOCK, JOHN HOWARD; TRAN-DUBE, MICHELLE BICH; WYTHES, MARTIN JAMES		
Patent No	Kind Code	Publ. Date	Application No	Filing Date	Indexed Patent
CA2969295	A1	2017/06/01	CA2969295	2017/06/01	
US2017/348313	A1	2017/06/02	US2017-612030	2017/06/02	
WO2017/212385	A1		WO2017-212385		
TW2018/2074	A		TW2018-2074		
UY37274	A		UY37274		
AR108763	A1		AR108763		
TW1637945	B	2018/10/11	TW2017-1637945		
TW2018/40570	A	2018/11/16	TW2018-40570		
AU2017279014	A1	2018/12/13	AU2017-279014		
SG112018104855	A	2018/12/28	SG112018-104855		
CO2018013105	A2	2018/12/28	CO2018-013105		
CL2018003504	A1	2019/02/01	CL2018-003504		
KR2019/15745	A	2019/02/14	KR2019-015745		

专利标记,
便于查询
该专利的
授权情况

专利Claim
便于理解
专利的发明内容

Claims

1. A structure of formula (I) compound of formula or a stereoisomer thereof, tautomers or its pharmaceutically acceptable salt or solvate or prodrug: Wherein

R₁ Selected from hydrogen, halogen, C₁ - C₆ Alkyl, C₁ - C₆ C alkoxy and C₁ - C₆ Haloalkyl;

R₂ Selected from hydrogen, halogen, C₁ - C₆ C alkyl and C₁ - C₆ Haloalkyl;

R₃ Is selected from:

Each R₃ Independently selected from hydrogen, halogen, optionally substituted C₁ - C₆ Alkyl, C₁ - C₆ C alkoxy, hydroxy, amino or C₁ - C₆ Alkyl;

R₄ For the group - (CHR₄)₃ - (Y)₃ - (CHR₇)₃ - R₈ ;

R₆ , R₇ Independently selected from hydrogen, C₁ - C₆ Alkyl, hydroxy;

C Y is selected from: C₁ - C₆ Alkyl, NH or O;

R₈ C selected from optionally substituted C₂ - C₈ Heterocyclic alkyl, optionally substituted C₃ - C₈ Cycloalkyl, optionally substituted C₂ - C₁₀ Heteroaryl, substituted ethylenically H, C₁ - C₆ Alkyl, C₂ - C₈ Heterocyclic alkyl, C₃ - C₈ Cycloalkyl, - S(O₂) C₁ - C₆ Alkyl, - S(O) C₁ - C₆ Alkyl, - C(O) (CH₂)_w C₂ - C₈ Heterocyclic alkyl, C₂ - C₁₀ Heteroaryl, C₆ - C₁₀ Aryl, hydroxy or halogen. W is selected from 0, 1, 2;

S, t, u independently selected from 0, 1, 2.

2. In the formula (I) compound or its stereoisomers according to Claim 1, tautomers or its pharmaceutically acceptable salt or solvate or prodrug, characterized in that said R₃ Is selected from

3. In the formula (I) compound or its stereoisomers according to Claim 2, tautomers or its pharmaceutically acceptable salt or solvate or prodrug, characterized in that said R₃ Is selected from

4. In the formula (I) compound or its stereoisomers according to Claim 3, tautomers or its pharmaceutically acceptable salt or solvate or prodrug, characterized in that said R₄ Is - OCH₂ R₈ , - CH₂ R₈ , - R₈ ; R₈ Selected from the following group optionally substituted: oxo cyclopropane, oxetane, tetrahydrofuran, tetrahydro - 2H - pyran, pyran, azetidine, pyrrolidine, piperidine, morpholine, morpholine -3 - one or thiomorpholine 1, 1 - dioxide; substituted ethylenically H, C₁ - C₆ Alkyl, C₂ - C₈ Heterocyclic alkyl, C₃ - C₈ Cycloalkyl, - S(O₂) C₁ - C₆ Alkyl, - S(O₂) (CH₂)_w C₃ - C₈ Cycloalkyl, - S(O₂) (CH₂)_w C₂ - C₈ Heterocyclic alkyl, - C(O) C₁ - C₆ Alkyl, - C(O) (CH₂)_w C₃ - C₈ Cycloalkyl, - C(O) (CH₂)_w C₂ - C₈ Heterocyclic alkyl, C₂ - C₁₀ Heteroaryl, C₆ - C₁₀ Aryl, hydroxy or halogen.

5. In the formula (I) compound or its stereoisomers according to Claim 4, tautomers or its pharmaceutically acceptable salt or solvate or prodrug, characterized in that said R₄ Selected from the following

Case 4: 检索2019年2月，与CD137相关的，人用药，含抗原或抗体的医药配置品（生物药类专利）

The screenshot shows the Reaxys Query Builder interface. The search criteria are as follows:

- Group 1: Patents: Main IPC OR Patents: Secondary IPC, both containing 'a61k 39/00'.
- AND: Document Basic Index containing 'cd137'.
- AND: Patents: Date of publication containing '2019/02'.

Annotations on the screenshot:

- Contains 便于快速模糊检索**: Points to the 'contains' operator in the query builder.
- IPC分类:人用药类A61K, 含抗体类39/00**: Points to the 'a61k 39/00' search term.
- 关键索引: CD137**: Points to the 'cd137' search term.
- 公开日期: 2019年2月 (注: 该公开日期为专利的最后一个公开日期, 不一定是首发。可能是族号, 可能是不同版本的最新公开日期, 如, A1, A2, B)**: Points to the '2019/02' search term.

4个模块同时组合, 并设定需要逻辑: A summary note indicating that all four search modules are combined with logical operators.

组合模块构建

Reaxys

Quick search Query builder Results Synthesis planner History

Search in: Reactions > Targets > Substances > **关键词模块**

Import Save Reset form Delete all

Structure Molecular Formula CAS RN **Doc. Index**

在Query Builder中只需要点击所需模块即可进行组合检索

Drag & Drop to build a new query

查询特定模块

Find search fields and forms
Q ipc

Reaxys ^

- ◇ Patents: Main IPC
- ◇ Patents: Secondary IPC

Feedback

检索结果

METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY ENGINEERED CELLS

2 JUNO THERAPEUTICS, INC.; BONYHADI, Mark L. WO2019/32929, 2019, A1

Patent Family Members: WO2019/32929 A1

Abstract Claims **Front Page Info** Full Text [↗](#)

Claims hit: {...of CD28, CD137 (4-1-BB), OX40, or ICOS.42. The method of claim 41, wherein...}

Assignees		Inventors (Authors)	
JUNO THERAPEUTICS, INC.; BONYHADI, Mark L.		BONYHADI, Mark L.	
Patent No	Kind Code	Publ. Date	Application No
WO2019/32929	A1	2019/02/14	WO2018-US46151
Priority No	公开日期 授权状况		Priority Date
US2017-543359P			2017/08/09
Patent Classification			
Main IPC	IPC 分类		
A61K 39/00			
Secondary IPC	C12N 5/0783		

Claims

CLAIMS

WHAT IS CLAIMED:

1. A method for genetically engineering (a) incubating an input composition, under stimulating conditions, an input composition comprising T cells, wherein the stimulating conditions comprise the presence of one or more intracellular signaling domains of one or more costimulatory molecules, thereby generating a stimulated cell composition, and (b) introducing a nucleic acid encoding a genetically engineered recombinant receptor, wherein the method thereby generates cells expressing the genetically engineered recombinant receptor.
2. A method for genetically engineering a population of T cells comprising naive-like T cells, wherein the stimulating conditions comprise the presence of one or more intracellular signaling domains of one or more costimulatory molecules, thereby generating a stimulated cell composition, and (b) introducing a nucleic acid encoding a genetically engineered recombinant receptor, wherein the method thereby generates cells expressing the genetically engineered recombinant receptor.
3. The method of claim 1 or claim 2, wherein the incubating is carried out for at least 3 days.
4. The method of claim 1 or claim 2, wherein the incubating is carried out for at least 4 days.
5. The method of claim 1 or claim 2, wherein the incubating is carried out for at least 5 days.
6. The method of claim 1 or claim 2, wherein the incubating is carried out for at least 6 days.
7. A method for stimulating T cells, the method comprising:
 - (a) incubating, under stimulating conditions, an input composition comprising T cells comprising a culture-initiating amount of naive-like T cells or a CD8+ stimulated composition, wherein the stimulating conditions comprise the presence of a stimulatory reagent capable of activating one or more intracellular signaling components of a TCR complex and/or one or more intracellular signaling domains of one or more costimulatory molecules, thereby generating a stimulated cell composition, and
 - (b) introducing into the stimulated cell composition a nucleic acid encoding a genetically engineered recombinant receptor, wherein the method thereby generates cells expressing the genetically engineered recombinant receptor.


专利‘Claim’部分的摘取和可索引，对于生物药类专利的检索非常有利。

通常生物药类的专利，不具有结构式，且专利标题和摘要一般会撰写得比较简单，造成了生物药类专利检索的困难

基于全新化合物评估的Markush检索

- Markush检索概览

Markush A结构
包含范围及实
施例




Markush B结构
包含范围及实
施例

Markush C结构包含
范围，必须保证覆盖
范围没有实施例，才
有可能被授权

Markush检索的基本模式



➤ Reaxys数据库中markush检索需要手动分辨结构分子的新颖性




	0	Substances	Structure : as drawn	直接检索结果为零
	0	Targets	Structure : as drawn	
	0	Substances	Structure : average similarity; included: only absolute stereo, additional ring closures allowed, salts, mixtures, isotopes, charges, radicals	
	0	Reactions	Reaction Query : as drawn	

Markush检索的基本模式

- 通过分析之后，可以通过相似已存在结构的markush锁定结果



方法1：相关性最高检索



方法2：限定一定范围的检索

Markush检索的基本模式-方法1：最相关结构检索

Reaxys® Quick search Query builder Results Synthesis planner History Register > Sign in

Structure editor ChemAxon's MarvinJS Create structure template from name >

Search this structure as:
 As drawn
 As substructure
 Similar
 Tautomers
 Stereo
 Additional ring closures
 Related Markush
 Salts
 Mixtures
 Isotopes
 Charges
 Radicals

Markush检索，会把‘结构式’中确切的部分去匹配专利中的‘实施例结构’命中相关专利

整个分子都是确切结构

除开‘G’官能团的剩下部分是确切结构

注意关联Markush其余的‘异构体’选项请关闭以避免干扰

Markush检索的基本模式-检索结果

Reaxys

Quick search Query builder Results Synthesis planner History

Register > Sign in

11 Substances out of 6,211 Documents, containing 116 Reactions, 1,069 Targets

1 selected Limit To Exclude Export

Sort by No of References ↓ Grid Heatmap

1 gefitinib
C22H24N4ClF3 44
Identification
Druglikeness
Physical Data - 88
Other Data - 2,972

2
Reaxys ID: 11329531
11329531
Identification
Other Data - 3
Documents - 1 >

3
Reaxys ID: 18419582
18419582
Identification
Other Data - 42
Documents - 1 >

4
Reaxys ID: 20784707
20784707
Identification
Documents - 1 >

Feedback

排除第一个结构所包含的文献, 即为10个Markush结构对应的专利

方法1: 相关性最高检索检索结果中, 除去第一个为所画结构本身, 剩下的结构均为, 包含该“具体结构为实施例”的专利中“Markush结构”

Markush检索的基本模式-检索结果

10 Substances out of 9 Documents, containing 0 Reactions, 0 Targets

10个‘Markush’结构, 9篇专利


Reaxys - 10

0 selected Limit To Exclude Export

Sort by No of References ↓ Grid Heatmap

Documents - 1 >


1



Reaxys ID: 11329531
11329531

Identification
Other Data - 3


2



Reaxys ID: 18419582
18419582

Identification
Other Data - 42


3



Reaxys ID: 20784707
20784707

Identification

4



Reaxys ID: 23992506
23992506

Identification
Other Data - 5

9 Documents with 10 Substances, 0 Reactions, 0 Targets

Reaxys - 9

0 selected Limit To Exclude Export

Sort by Publication Year ↓ Heatmap

1 A preparation method of gefitinib (by machine translation)
Lunan Pharmaceutical Group Co., Ltd.; Zhang Guimin; Dong Huaimin; Yu Junhou - CN108727284, 2018, A
Abstract Claims Front Page Info Substances 9 Reactions 12 Full Text
Hit Substances 2

2 Quinazoline derivatives and use thereof (by machine translation)
Zhengzhou University The First Affiliated Hospital; Cheng Weiyan; Zhang Xiaojian; Tian Xin - CN106432202, 2017, A
Patent Family Members: CN106432202 A; CN106432202 B
Abstract Claims Front Page Info Substances 21 Reactions 19 Full Text
Hit Substances 2

3 PROCESS FOR PREPARING QUINAZOLINE DERIVATIVE
SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD.; ZHANG, Xiaoheng; LV, Xizhou - WO2015/188318, 2015, A1
Patent Family Members: CA2914990 A1; WO2015/188318 A1; AU2014389984 A1; TW2016/2085 A; CN105377820 A; ...
Abstract Claims Front Page Info Substances 14 Reactions 28 Full Text
Hit Substances 2

4 COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE
NOVARTIS AG; TIEDT, Ralph; CHATENAY-RIVAUDAY, Christian; ITO, Moriko; PENG, Bin; GONG, Ying; AKIMOV, Mikhail - WO2013/149581, 2013, A1
Patent Family Members: WO2013/149581 A1; CA2868202 A1; AU2013243097 A1; CN104245701 A; KR2015/1782 A; ...
Abstract Claims Front Page Info Substances 6 Targets Full Text
Hit Substances 2

5 SMALL MOLECULE COMPOUNDS FOR TARGETING INFLAMMATORY CONDITIONS
Brooks, Marvin B. - US2013/281448, 2013, A1
Patent Family Members: WO2013/158482 A1; US2013/281448 A1; US2015/31695 A1
Abstract Claims Front Page Info Substances 5 Full Text
Hit Substances 3


6 Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline
Shih, Kae-Shyang; Hsieh, Yu-Jung; Liu, Ching-Wei - US2010/267949, 2010, A1
Patent Family Members: CN101863844 A; US2010/267949 A1; CN101863844 B
Abstract Claims Front Page Info Substances 27 Reactions 18 Full Text
Hit Substances 2



ELSEVIER

Markush检索的基本模式-方法2：一定范围扩展结构检索

➤ 需要进一步检索新颖性时，可进行一定范围限定的扩展检索



The screenshot displays the Reaxys software interface. The main window shows a chemical structure editor with a Markush structure. The structure consists of a benzimidazole core. One benzimidazole ring is substituted with a fluorine atom (F) and a chlorine atom (Cl) on the benzene ring, and an NH group. The other benzimidazole ring is substituted with a 'G' group and a methoxy group (O-CH₃) on the benzene ring. The 'G' group is highlighted in green. The interface includes a top navigation bar with 'Quick search', 'Query builder', 'Results', 'Synthesis planner', and 'History'. On the right side, there is a search options panel titled 'Search this structure as:' with the following options: 'As drawn' (selected), 'As substructure', 'Similar', 'Tautomers', 'Stereo', 'Additional ring closures', 'Related Markush', 'Salts', 'Mixtures', 'Isotopes', 'Charges', and 'Radicals'. There is also a '+ More options' link. At the bottom right, there are buttons for 'Clear', 'Cancel', and 'Transfer to query', along with a 'Feedback' button.

Reaxys[®] Quick search Query builder Results Synthesis planner History Register > Sign in

Structure editor ChemAxon's MarvinJS Create structure template from name >

Search this structure as:

- As drawn
- As substructure
- Similar
- Tautomers
- Stereo
- Additional ring closures
- Related Markush
- Salts
- Mixtures
- Isotopes
- Charges
- Radicals
- + More options

除开‘G’官能团的剩下部分是‘确切结构’，索引实施例包含确切结构的专利

Clear Cancel Transfer to query Feedback

Markush检索的基本模式-检索结果

Reaxys[®] Quick search Query builder Results Synthesis planner History Register > Sign in

1,341 Substances out of 6,429 Documents, containing 2,813 Reactions, 1,125 Targets

0 selected Limit To Exclude Export

Sort by No of References ↓ Grid Heatmap

Reaxys - 1,341

1 gefitinib
C22H24N4ClFO3 446.909 8949523 184475-35-2

Identification Bioactivity (All) Spectra - 65 Preparations - 76 >
Druglikeness Physical Data - 88 Other Data - 2,972 Reactions - 116 >
Targets - 1,069 >
Documents - 6,211 >

2

3

4

Spectra - 17

Preparations - 41 >
Reactions - 254 >
Targets - 7 >
Documents - 72 >

Preparations - 3 >
Reactions - 3 >
Targets - 81 >
Documents - 44 >

Preparations - 13 >
Reactions - 109 >
Documents - 28 >

Feedback

1.34 K Filters

Limit to > Exclude >

By Structure >
Measurement pX >
Highest Clinical Phases >
Targets >
Parameters >
Substance Classes >
Molecular Weight >
Number of Fragments >
Availability >
Availability in other databases >
Available Data >
Document Type >
Publication Year >
Patent Assignee >
LogP >
H Bond Donors >
H Bond Acceptors >
Rotatable Bonds >
TPSA >

在结果集中筛选‘无分子量’的‘Markush’

Molecular Weight

Clear selected x ↓ ↑ Sort by Occurrence v x

<input type="checkbox"/>	>816 - 828	1
<input type="checkbox"/>	>780 - 792	1
<input type="checkbox"/>	>768 - 780	1
<input type="checkbox"/>	>744 - 756	1
<input type="checkbox"/>	>720 - 732	1
<input type="checkbox"/>	>708 - 720	1
<input type="checkbox"/>	>672 - 684	1
<input type="checkbox"/>	>660 - 672	1
<input type="checkbox"/>	>336 - 348	1
<input checked="" type="checkbox"/>	(no entry given)	90

< 1 2 3 > Limit to > Exclude >

Markush检索的基本模式-检索结果

Reaxys® Quick search Query builder **Results** Synthesis planner History Register Sign in

90 Substances out of 63 Documents, containing 16 Reactions, 1 Targets

90个 'Markush' 结构, 63篇专利

63 Documents with 90 Substances, 16 Reactions, 1 Targets

A benzo nitrogen hetero-aromatic ring compound and its preparation method and application (by machine translation)
No author - CN107674059, 2018, A
Patent Family Members: CN107674059 A
Abstract Claims Front Page Info Substances 73 Reactions 107 Full Text
Hit Substances 3

A model of the Buddhist compound
Beijing University of Chemical Technology; Q
Patent Family Members: CN108047209 A
Abstract Claims Front Page Info
Hit Substances 10

Lian xi amide-group-containing compound or protein labeling application in (b
Peking University; Lei Xiaoguang; Li Qiang; L
Patent Family Members: CN108148006 A
Abstract Claims Front Page Info
Hit Substances 5

Identification

Claims

1. The formula I shows the benzene and nitrogen hetero-aromatic ring compound or its pharmaceutically acceptable salts, stereoisomers, racemic modification, or a prodrug or solvate:
R and R' in one of the substituted group is selected from The other substituted the base elects from the hydrogen, methoxy, methoxyethoxy,
R'' is a substituted or unsubstituted phenyl, phenyl substituted group is selected from halogen, -NO₂, -CN, -OH, R¹R²N-, (3-fluorophenyl) methoxy, C₁₋₆ Alkyl, halogen substituted C₁₋₆ Alkyl, C₂₋₆ Alkenyl, C₂₋₆ Alkynyl, C₃₋₆ Cycloalkyl, C₁₋₆ Alkoxy, halogen-substituted C₁₋₆ Alkoxy, C₃₋₆ Naphthenic oxy; R¹, R² Are respectively independently represent H, C₁₋₆ Alkyl;
Wherein Q is selected from
L¹ C selected from C₂₋₈ Alkyl, C₂₋₆ Alkenyl, C₂₋₆ Alkynyl, C₃₋₆ Cycloalkyl, and L¹ In S can then be¹ Substituted;
A¹ Is selected from -O-, -NH-, S(=O)_m, Amide linkage, ester bond (-COO-), (-COS-) thioester bond, disulfide bond, double bond [...], n-O or covalent bond, and A¹ In S can then be² Substituted;
L² Said C₂₋₈ Alkyl, C₂₋₆ Alkenyl, C₂₋₆ Alkynyl, C₃₋₆ Cycloalkyl or covalent bond, and L² In S can then be³ Substituted;
A² Said -O-, -NH-, S(=O)_m, C₁₋₆ Alkyl, C₂₋₆ Alkenyl, C₂₋₆ Alkynyl, C₃₋₆ Cycloalkyl, and A² In S can then be⁴ Substituted;
M=0, 1 or 2;
S¹, S², S³ And S⁴ Are independently selected from -CN, -CF₃, -CO₂H, halogen, C₁₋₆ Alkyl, C₃₋₆ Cycloalkyl, C₂₋₆ Alkenyl, C₂₋₆ Alkynyl, R³O-, R³R⁴N-, R³S(=O)_m-, R³R⁴NS(=O)_m-, R³R⁴NC(=O)-, R³R⁴NC(=O)O-, R³OC(=O)-, R⁵C(=O)-, R⁵C(=O)NR³-, R³R⁴NC(=O)NR⁶-, R³OC(=O)NR⁶-, R³S(=O)_mNR⁶-, R³R⁴NS(=O)_mNR⁶-, R³R⁴NC(=NR⁷)NR⁶-, R³R⁴NC(=CHNO₂)NR⁶-, R³R⁴NC(=N-CN)NR⁶-, R³R⁴NC(=NR⁷)-, R³S(=O)(=NR⁷)NR⁶- Or R³R⁴NS(=O)(=NR⁷)-;
R³, R⁴, R⁵, R⁶ And R⁷ Are respectively independently represent H, C₁₋₆ Alkyl, C₃₋₆ Cycloalkyl, C₂₋₆ Alkenyl, C₂₋₆ Alkynyl; when R³ And R⁴ Connected to the same nitrogen atom when on, together with the nitrogen atom can form a C₃₋₁₂ Heterolipid ring, this C₃₋₁₂ Heterolipid ring can include O, N, S(=O)_m The hetero atom; and R³, R⁴, R⁵, R⁶ And R⁷ Testing gas channel can be halogen, CN, C₁₋₆ C alkyl or C₃₋₆ Cycloalkyl substituted.





2. Benzo nitrogen hetero-aromatic ring compound according to Claim 1, characterized in that R and R' in one of the substituted group is selected from The other substituted the base elects from the hydrogen, methoxy, methoxyethoxy, R'' is a substituted or unsubstituted phenyl, phenyl substituted ethynyl group is selected from, F, Cl, Br, (3-fluorophenyl) methoxy, -NH₂, -N(CH₃)₂;
Wherein Q is selected from
L¹ Is selected from -(CH₂)_t-, T is 2-8 integer;
A¹ Is selected from -O-, -NH-, -NH- in C can then be C₁₋₆ Alkyl substituted, -S-, -SO-, -SO₂- Or a covalent bond;
L² Is selected from -(CH₂)_n-, N is 0-8 integer;
A² Is selected from -O-, -NH-, -S-, -SO-, -SO₂-.

3. Benzo nitrogen hetero-aromatic ring compound according to Claim 2, characterized in that R and R' in one of the substituted group is selected from The other substituted the base elects from the hydrogen, methoxy, R'' is a substituted or unsubstituted phenyl, phenyl substituted ethynyl group is selected from, F, Cl, Br, (3-fluorophenyl) methoxy, phenyl may be mono-substituted, can also be a multi-substituted;
Wherein Q is selected from
L¹ Is selected from -(CH₂)_t-, T is 2-7 of the integer;
A¹ Is selected from -O-, -NH-, -NH- in C can then be C₁₋₃ Alkyl substituted or covalent bond;
L² Is selected from -(CH₂)_n-, N is 0-2 integer;
A² Is selected from -O-, -NH-, -S-, -SO₂-.

专利的 'claim' 可以直接展开阅读

CASE 5: 评估以下化合物的可专利性

➤ 当有多个分子需要同时评估时，可设计Markush结构



Reaxys中的Markush检索

Reaxys

Quick search Query builder Results Synthesis planner History

Sam Yu

Structure editor

Create structure template from name >

R₁

R₂

R₃

R₁=

R₂=

R₃=

Search this structure as:

- As drawn
- As substructure
 - On all atoms
 - On heteroatoms
- Similar

Include

- Tautomers
- Stereo
- Additional ring closures
- Related Markush
- Salts
- Mixtures
- Isotopes
- Charges
- Radicals

+ More options

Clear Cancel Transfer to query

Feedback

利用分子量筛选，筛出Markush结构

Reaxys[®] Quick search Query builder Results Synthesis planner History Sam Yu

37 Filters and Analysis 448

By Structure Measurement pX Highest Clinical Phases Targets Parameters Substance Classes Molecular Weight (no entry given) 37 Availability Availability in other databases Available Data Document Type Publication Year




37 Substances out of 28 Documents, containing 11 Reactions, 0 Targets

0 selected Link To Exclude Export Sort by No of References Heatmap


1 Reaxys ID: 11329531 11329531 Identification Other Data - 3 Documents - 1

2 Reaxys ID: 11334491 11334491 Identification Other Data - 4 Documents - 1

3 Reaxys ID: 12250782 12250782 Identification Documents - 1




Markush结构的解析



有时候，根据每篇专利的发明情况不同，可能会出现多个markush结构。Reaxys中的Markush标记出该结构在专利Claim中的位置

Reaxys ID: 12250782
12250782

Identification Documents - 1 >



Identification

Reaxys ID: 12250782

Chemical Names:

CAS Registry Number(s):

Molecular Formula:

Molecular Weight:

InChIKey:


Location in Patent	Reference
Claim 24	ASTRAZENECA AB; ASTRAZENECA UK LIMITED - WO2005/30757, 2005, A1 Full Text ↗ Show details >

Substance Label - 1

Patent-Specific Data - 1

Rx辅助专利中Markush结构的解读

24. A quinazoline derivative according to any one of the preceding claims having a structural sub-formula A2



wherein:


m is 2 and R^1 is 2-fluoro and 3-chloro;

R^2 is methoxy;

R^3 is methyl;


n is 0;

Markush结构查新仅仅是起始，对于重要化合物保护专利，Markush结构的解读便于分析该专利排他性范围到底如何。



专利原文中对该结构的描述

24. A quinazoline derivative according to any one of the preceding claims having a structural sub-formula A2



wherein:

- m is 2 and R¹ is 2-fluoro and 3-chloro;
- R² is methoxy;
- R³ is methyl;
- n is 0;

专利原文用文字进行结构的描述，
较为复杂，不易阅读

WO 2005/030757


- 184 -

PCT/GB2004/004085

and R⁵ is hydrogen or (1-6C)alkyl and R⁶ is selected from substituted-(1-6C)alkyl (wherein substituted-(1-6C)alkyl is (1-6C)alkyl substituted by 1, 2 or 3 substituents independently selected from (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino, and oxo or a (1-6C)alkoxycarbonyl together with a hydroxy group), (1-6C)alkoxy, (1-6C)alkylsulfonyl, (3-7)heterocyclyl (wherein the heterocyclyl is carbon linked), heteroaryl, (3-7)heterocyclyl(1-6C)alkyl (wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety) and heteroaryl(1-6C)alkyl, and wherein any heteroaryl or (3-7)heterocyclyl group within R⁶ is optionally substituted (on any available carbon atoms) by 1, 2 or 3 substituents independently selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy, and wherein any heteroaryl or heterocyclyl group within R⁵ is optionally substituted on any available ring nitrogen (provided the ring is not thereby quaternised) by (1-4C)alkyl or (2-4C)alkanoyl, or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which contains one or two nitrogen atoms as the only heteroatoms present in the ring and which is optionally and which is substituted on an available ring carbon atom by 1 or 2 substituents independently selected from carbamoyl and (1-3C)alkylenedioxy.

25. A quinazoline derivative according to claim 24, wherein R⁶ is selected from (3-7)heterocyclyl (wherein the heterocyclyl is carbon linked), heteroaryl, (3-7)heterocyclyl(1-6C)alkyl (wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety) and heteroaryl(1-6C)alkyl, and wherein any heteroaryl or (3-7)heterocyclyl group within R⁶ is optionally substituted (on

Reaxys将结构翻译成图表



图表形式的解读更容易帮助理解结构保护的范

Label	Value	Size	Attributes	Substituted by	Frequency
R2	methoxy				
R3	methyl				
R5	hydrogen				
R6	alkyl	1-6C		\$\$8	0-3
	hydrogen				
	alkyl	1-6C			
	alkenyl	2-8C			
	alkynyl	2-8C			
	alkoxy	1-6C			
	cycloalkyl	3-7C			
	alkylsulfonyl	1-6C			
heterocyclyl				\$\$9	0-2
heteroaryl					
	\$\$*cyclalk37\$*alk13				
	\$\$*hetar\$*alk13				
	\$\$*hets\$*alk13				
\$\$1	alkyl	1-4C			

内容

➤ Elsevier 生命科学解决方案

1. Reaxys对信息的提炼介绍，以及信息检索基础技巧
2. Reaxys专利检索策略
3. RMC辅助药物分子设计研发决策
4. PharmaPendium辅助药物临床研究

➤ 总结

RMC辅助药物分子设计研发决策


- 对文献数据的处理
- 特定信息检索功能
- 辅助药物分子改性

查看具体的生物数据

231 Substances out of 2,394 Documents, containing 1,199 Reactions, 65 Targets

0
 Limit To
 Exclude
 Export

1



Reaxys ID: 4194670

C₁₅H₂₂O₅ 282.337 4194670 63968-64-9

Identification

Druglikeness

Bioactivity (All)

Physical Data - 375

Spectra - 102



^ Bioactivity (All)

- ✓ In vitro: Efficacy - 1,358
- ✓ In vivo: Animal Model - 135
- ✓ Metabolism - 160
- ✓ Pharmacokinetic - 98
- ✓ Toxicity/Safety Pharmacology - 343

pX	Parameter	Value (qual)	Value (quant)	Unit	Biological Species	Population	Route of administration	Dose	Dosing regimen	Reference
	metabolic stability	active			mouse		administration	mg/kg		Acquaah-Mensah, George K.; Rich, Stephen M. - Journal of Ethnopharmacology, 2014, vol. 153, # 3, p. 732 - 736 Full Text Cited 15 times Details Abstract
	Vd ss/F		1363	L	Human	Healthy	oral administration	500 mg	Single	Simonsson, Ulrika S. H.; Jansson, Britt; Hai, Trinh Ngoc; Huong, Dinh Xuan; Tybring, Gunnel; Ashton, Michael - Clinical Pharmacology and Therapeutics, 2003, vol. 74, # 1, p. 32 - 43 Full Text Cited 68 times Details Abstract
	Vd ss/F		967	L	Human	Healthy	oral administration	500 mg	Single	Simonsson, Ulrika S. H.; Jansson, Britt; Hai, Trinh Ngoc; Huong, Dinh Xuan; Tybring, Gunnel; Ashton, Michael - Clinical Pharmacology and Therapeutics, 2003, vol. 74, # 1, p. 32 - 43 Full Text Cited 68 times Details Abstract
	AUC		1696	ng.h/mL	Human	Healthy	oral administration	500 mg	Single	Simonsson, Ulrika S. H.; Jansson, Britt; Hai, Trinh Ngoc; Huong, Dinh Xuan; Tybring, Gunnel; Ashton, Michael - Clinical Pharmacology and Therapeutics, 2003, vol. 74, # 1, p. 32 - 43 Full Text Cited 68 times Details Abstract

单个化合物全部生物活性的导出

Reaxys

Quick search Query builder Results Synthesis planner History Register > Sign in

1 Filters

145 Limit to > Exclude >

By Structure >

Measurement pX >

Highest Clinical Phases >

Targets >

Parameters >

Substance Classes >

Molecular Weight >

Number of Fragments >

Availability >

Availability in other databases >

Available Data >

Document Type >

Publication Year >

Patent Assignee >

LogP >

H Bond Donors >

H Bond Acceptors >

Rotatable Bonds >

TPSA >

1 Substances out of 4,158 Documents, contain

0 selected Limit To Exclude Export

1

Export substances Reaxys

Choose a format: **Microsoft Excel**

Range: All results - 1

Export:

- All available data
- Identification data only
- Hit data only
- Choose specific data + Add datapoints

Additional options: Include structures

1: 选择Excel

2: 选择

Export substances

<input checked="" type="checkbox"/> Medicinal Chemistry		<input checked="" type="checkbox"/> Bioactivity	
<input type="checkbox"/> Other Data	1	<input type="checkbox"/> Druglikeness	1
<input type="checkbox"/> Physical Data	1		
<input type="checkbox"/> Spectra	1		

Preparations - 111 >

Reactions - 987 >

Targets - 76 >

Documents - 4,158 >

ELSEVIER Copyright © 2019 Elsevier Life Sciences IP Limited.

Terms and Conditions Privacy policy About content Performance Page

Cookies are used by this site. To decline or learn more, visit our Cookies page

导出整理excel表格

The screenshot shows the Microsoft Excel interface with the following elements:

- Find and Replace Dialog:** A dialog box is open with the 'Find' tab selected. The 'Find what:' field contains the text 'parameter'.
- Sort & Filter Dropdown:** A dropdown menu is open, showing various sorting and filtering options. The 'Activity' checkbox is checked.
- Spreadsheet Data:** The spreadsheet contains columns for chemical structures, SMILES, Substance Links, CAS numbers, and various parameters. The 'Activity' column is highlighted in green.

筛选各种需要数据

RMC-针对专利数据的快速导出

Reaxys® Quick search Query builder Results Synthesis planner History Register > Sign in ⓘ

Search in: Reactions > Targets > Substances > Documents >

Find search fields and forms
patent

Import Save Reset form Delete all

Structure Molecular Formula CAS RN Doc. Index


Common Patent Number is WO2018/119266

Query Builder界面有针对专利检索的各种模块
'common patent number' 通过专利号检索专利

WO2009/020825 (专利原文号需要处理成以下形式再检索)
加工后的专利号: WO2009/20825
WO2009*20825

Feedback

快速摘取专利中的生物活性数据



1 Documents with 196 Substances, 397 Reactions, 1 Targets

0 selected Limit To Exclude Export

HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS

1 Incyte Corporation; Wu, Liangxing; Qian, Ding-Quan; Lu, Liang; Wenqing US2018/177784, 2018, A1
Patent Family Members: TW2018/35073 A; US2018/177784 A1; U
Abstract Claims Front Page Info Substance

Heatmap

Heatmap settings

Value of X-axis

Value of Y-axis

Value of Cells

Show substances Names Structure drawing

Display mode Normal Full Screen

Always show settings

通过热图按钮，建立测量数据与化合物构效关系

导出该篇专利的信息

Limit To Exclud Export Settings Navigator Legend Documents Exit Full Screen

Export substances and bioactivities

Choose a format: Microsoft Excel

Range: All results - 196

Export: All available data Hit data only Choose specific data

Additional options: Include structures

Export >

Tab-delimited text

- Microsoft Excel
- Tab-delimited text
- XML
- SD/Molfile

Substances

(S)-1-((8-(2-N-(5-chloro-6-(2-methyl-2-((2-(2-methyl-N-(2-methyl-N,N-dimethyl-3-(2-methyl-2-(6-(2-methyl-2-((2-(2-methyl-3-(2-methyl...oacetate

(4-(3-methyl...oacetate

cis-4-((5-(3-...oacetate



Navigator

Feedback

1. 导出时，选择 ‘hit data’
- ic50 2. 导出 ‘excel’ 会包含结构式图片
3. 导出 ‘Tab’ 不会包含结构式图片

简单整理Excel表格即可规整数据

The screenshot shows an Excel spreadsheet with a table of chemical data. The table has columns for chemical structures, SMILES strings, and various identifiers. A yellow box highlights the first three steps of the process: selecting all data, clicking 'Find', and searching for 'parameter'. The 'Find and Replace' dialog box is open, showing the search term 'parameter' and the 'Find Next' button highlighted.

Structure: Image	SMILES	Substance	Links to ReData	Coun	CAS Regist	Chemical	Linear Stru	Molecular	Molecular	Type of Su	Type and I	InChI Key	Compositi	Compositi	Compositi
	<chem>NC1=CC=</chem>	(605631													
	<chem>CC(C)(C)OC</chem>	1911173	https://www.2of196	24424-99-di-tert-but	((C4H9)OC	C10H18O5	218.25	acyclic				DYHSDKLC			

打开表格后：
1. 全选所有数据
2. 点击查找
3. 查找 'parameter'

Find and Replace
Find what: parameter
Find Next

简单整理Excel表格即可规整数据

Clipboard: Cut, Copy, Paste, Format Painter

Font: 等线, 11, Bold, Italic, Underline, Color, Background Color, Font Color, Text Color, Font Size, Font Style

Alignment: Wrap Text, Merge & Center, Text Alignment, Orientation

Number: General, Currency, Percentage, Decimals, Thousands Separator

Styles: Conditional Formatting, Format as Table, Cell Styles

Cells: Insert, Delete, Format

Editing: AutoSum, Fill, Clear, Sort & Filter, Find & Select

	CH	CI	CJ	CK	CL	CM	CN	CO	CP	CR	CS	CT	CU	CV	CW	CX	CY	
1	Cell Fractic	Substance	Links to Re	Smiles	Substance	Substance	Substance	Substance	Qualitative	Measure	Unit	Measur	Medchem:	Quantitati	Deviation	Statistical	Statistical	Measurem
2																		

Reaxys Export 20190407_111908

Sort & Filter menu options:

- Sort A to Z
- Sort Z to A
- Sort by Color
- Clear Filter From "Measurement Param..."
- Filter by Color
- Text Filters
- Search
- (Select All)
- IC50
- (Blanks)

OK

查找到 'parameter' 之后，建立 'filter'，并查看筛选需要数据即可


筛选的目的是排除掉 'blank' 中包含的没有数据的事实结构，当专利中有多种数据时，也可以快速选择

整理结果



‘SMILES’(可转化为结构), 数据类型, 单位, 数值, 原文, 原文连接

	A	B	C	D	E	F	H	I	J	K	L	M	N	O	P
1	Structure	Bioassay Category	Measu	Unit	Medchem:	Quantitative	References	Links to Reaxys							
2	CN1CCN(CC2=CC=C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
3	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
4	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
5	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
6	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
7	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
8	N[C@H]1CC[C@H]	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
9	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
10	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
11	CCCC(C)C1=NC=C	In Vitro (Efficacy)	IC50	nM		100 - 1000	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
12	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
13	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
14	CCCCNC1=NC=C2C	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							
15	O[C@H]1CC[C@H]	In Vitro (Efficacy)	IC50	nM	<	10	Patent, THE UNIVERSI	https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR=35474696&data							

Table 2 describes compounds prepared following procedures described in Example 2 (General Procedure B), using appropriate reagents. (Note: Mer IC50: +++ means < 10 nM; +++ means between 10-100nM, ++ means between 100 nM-1 μM; + means between 1-30 μM; - means inactive.)

Structure	Compound_ID	Mer IC50	Physical Data MS m/z (M+1) or/and ¹ H NMR (400 MHz, CD ₃ OD)
	UNC1970A	++++	¹ H NMR (400 MHz, CD ₃ OD) δ 8.75 (s, 1H), 7.81 (s, 1H), 7.71-7.62 (m, 2H), 7.25-7.16 (m, 2H), 4.72-4.60 (m, 1H), 3.55 (t, J = 7.1 Hz, 2H), 2.30-2.22 (m, 2H), 2.23-2.03 (m, 4H), 1.79-1.63 (m, 4H), 1.55-1.44 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H); MS m/z 382.25 [M+H] ⁺ .

Reaxys把原文中的图形结果, 进行了数字化翻译

Structure: Image	SMILES	Molecular	Molecular	InChI Key	LogP	TPSA	Lipinski Nu	Veber Nun	Target Nar	Measur
	CCCC(=O)C	C28H28N6	496.569	TYDXNFSX	4.98	114.05	4	1	Rho-associ	IC50
	CCCC(=O)C	C28H28N6	496.569	TYDXNFSX	4.98	114.05	4	1	Rho-associ	IC50

RMC-特定的信息检索方法

◇ Target Name	⋮
◇ Substance Action on Target	⋮
◇ Substance Effect	⋮
◇ Measurement pX	⋮
◇ Target Nature	⋮
◇ Target Mutant/Chimera Details	⋮
◇ Target Transfection	⋮
◇ Substance RN	⋮
◇ Substance Route of Adm.	⋮
◇ Substance Dosing Regimen	⋮

◇ Biological Material Name	⋮
◇ Biological Species	⋮
◇ (Clinical) findings / disease	⋮
◇ Organs/Tissues	⋮
◇ Cells/Cell Lines	⋮
◇ Cell Fraction	⋮
◇ Measurement Parameter	⋮
◇ Measurement Qualitative	⋮
◇ Measurement Unit	⋮

Substance Action on Target Search ×

<input type="checkbox"/> activator	75,140
<input type="checkbox"/> agonist 激动剂	,929
<input type="checkbox"/> allosteric modulator	,961
<input type="checkbox"/> antagonist	,683
<input type="checkbox"/> blocker 阻断剂	160,460
<input type="checkbox"/> inactivator	1,996
<input type="checkbox"/> inhibitor 抑制剂	10,470,915
<input type="checkbox"/> inverse agonist	13,321
<input type="checkbox"/> irreversible antagonist	3
<input type="checkbox"/> irreversible inhibitor	83
<input type="checkbox"/> modulator	313,006

1 of 2 Go to page Clear selected Transfer

检索对靶点作用机制的特点信息时的模块

Measurement Parameter is Enter search term ×

> cellular parameters	94,814
> epidemiological data	120,359
> in-vitro pharmacological parameters	20,175,771
> in-vivo pharmacological parameters	46,741
> mathematical parameters	148,038
> medical parameters	32,006
> metabolic parameters	54,026
> metabolism/transport parameters	110,315
> microbiological parameters	286,015
> pharmacokinetic parameters	835,343
> absorption parameters	59,818
> F (drug bioavailability)	56,062
> kabs	1,550
> MAT (mean absorption time)	7
> t1/2 abs	589
> tlag	1,582

Transfer


直接检索特定数据时的模块如PK的各种数据

各种分类细致的信息检索模块，快捷锁定对应结果



RMC-组合信息便捷检索

预设的组合检索模块，便捷检索综合信息，如对于不同亚型的同类靶点，差异抑制性



靶点选择性检索

靶点名称

AND


抑制‘数量级’以‘mol’为单位换算，9=10的负9次方

COMBI

AND

Target Name	Operator	Value
Histone deacetylase 2	is	9
Histone deacetylase 8; Histone deacetylase [Neovison vison]; Histone deacetylase 10	is	8

选择性抑制结果-快速构建差异抑制构效关系图



RMC-组合信息便捷检索

- Affinity on target
- Cell proliferation: inhibition
- Selectivity Profile
- Animal models: Tumor xenografts
- Bioavailability
- Volume of distribution
- Absorption (Cmax, Cavg)
- Caco-2 permeability
- Caco-2 Active transport
- Blood-Brain Barrier Penetration (BBB)

- Cytotoxicity
- hERG inhibition
- Cytochrome inhibition (CYP3A4)
- Metabolism by cytochrome (CYP2D6)
- Microsomal stability
- Protein binding (blood, plasma)
- Cardiotoxicity

hERG inhibition

- Structure
Create Structure / Reaction Drawing
- AND
- Target Name
is Target Name 'Potassium voltage-gated channel subfamily H mem'
- AND
- Target Nature
is Target Nature 'wild'
- AND
- Measurement Parameter
is Measurement Parameter '%50';'K';'Kd';'kd'
- AND
- Measurement pX
Measurement pX



Caco-2 permeability

- Structure
Create Structure / Reaction Drawing
- AND
- Cells/Cell Lines
is 'Caco-2 cell line';'Caco-2'
- AND
- Measurement Parameter
is 'papp (a-b)';'papp (b-a)';'papp (transport)';'papp';'transport ratio';'transp'

只需要特定结构即可初步快速检索特殊信息

RMC-组合信息便捷检索

快速整理 ‘特定结构’ Caco-2 数据

A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
	[H][C@@]1	https://ww	(17 of 954)	363623-08	vinblastin	810.988	Caco-2 ce Papp (B-A cm/s			9.66E-06		Article; Act	https://www.reaxys.com/reaxys/se		
89															
	[H][C@@]1	https://ww	(17 of 954)	363623-08	vinblastin	810.988	Caco-2 ce Papp (A-B cm/s			1E-07		Article; Ca	https://www.reaxys.com/reaxys/se		

Reaxys Export 20190221_163528

RMC强大的组合式药物化学检索模块定义复杂问题

The screenshot displays the RMC search interface. At the top, there are navigation buttons for "Reactions", "Targets", "Substances", and "Documents". Below these are utility buttons: "Import", "Save", "Reset form", and "Delete all". On the right, there are search filters: "Structure", "Molecular Formula", "CAS RN", and "Doc. Index".

The main area shows a chemical structure of a molecule with a benzimidazole core. A fragment of the structure, consisting of a benzimidazole ring with a methyl group and a substituent 'G', is circled in orange. To the right of this structure is a text box with the Chinese text: "评估不同碎片结构, 对药物分子 IC50的影响" (Evaluate the influence of different fragment structures on the IC50 of drug molecules).

Below the structure, there are two search criteria defined in a list:
















- Target Name is epidermal growth factor receptor binding protein;Epidermal growth factor receptor;epidermal growth factor-activated receptor;EGFR;EGFR (100)
- Measurement Parameter is ic50

Two orange boxes highlight the search criteria: "靶点" (Target) points to the first criterion, and "参数" (Parameter) points to the second criterion.

同位置侧链，生物活性影响度评估



筛选出高活性化合物，获取设计灵感



以结构为基础，多种数据组合评估

7 8 9 10 11 12

13 14 15 16 17 18

19 20

33,096 Substances out of 3,529 Documents containing 53,980 Reactions, 1,863 Targets

Reaxys - 33,096

Substances Full Screen

Limit To Exclude Export Settings Navigator Legend

Parameter	auc	clint (intrinsic clearance)	emax	ed50	emax	gi50	k50	t1/2 el
Substances	*	*	*	*	*	*	●	*
(S)-N-(4-((3-... boxamide							9.4	
(4S,5R)-N-(4... boxamide							9.4	
N-(2-chloro-... fonamide							9.4	
N-(5-(3,5-di... -4-amine							9.4	
N-(5-(3,5-di... -4-amine							9.4	
6-(1-acryloyl... -4-amine							9.4	
(S)-N ⁶ -(1-acr... -diamine							9.4	
28395477							9.4	
27951527							9.4	
N-(3-bromo... -4-amine							9.4	
N-(3-bromo... -4-amine							9.4	
N-(3-chloro-... -4-amine							9.4	

内容

➤ Elsevier 生命科学解决方案

1. Reaxys对信息的提炼介绍，以及信息检索基础技巧
2. Reaxys专利检索策略
3. RMC辅助药物分子设计研发决策
4. PharmaPendium辅助药物临床研究

➤ 总结

PharmaPendium数据库涵盖的内容

PharmaPendium是唯一提供上市药物，临床前与临床，药效，药物安全与药代动力学、药物代谢与转运酶，药物不良反应报告等数据的一站式平台；同时还收录此领域的权威期刊书籍内容，如Meyler副反应大全和Mosby用药参考等，助力药物筛选和研发进程。

FDA & EMA所有的approval package (FDA: 1938年至今，EMA: 1995年至今)

2.29M+

FDA 审评文件

200K+

EMA 审评文件

9.45M+

FDA 药物不良
反应报告

673K+

FDA 咨询委员
会会议档案

Extracted Data: PK Module

MET Module

FDA AERS

Efficacy Module

DDI Risk

4450

种药物的可
检索信息

1.6M+

药代动力学信息

305K+

药物代谢与转运
酶信息

1.66M+

药物安全信息

2.45M+

药效信息

115K+

生物活性信息

Pharmapendium辅助解决临床前，临床，以及上市后信息检索的需求/挑战



<p>药物安全与毒理 (Safety, Toxicity)</p> <ul style="list-style-type: none">➢ 支持临床前动物毒理数据分析➢ 支持临床人体毒理研究➢ 辅助临床试验方案决策➢ 更好地预测候选药物的潜在毒性	<p>药物代谢，转运酶及药物相互作用 (MET&DDI)</p> <ul style="list-style-type: none">➢ 查找获批药物的代谢酶、转运体的相关数据，辅助在研项目的决策➢ 基于已有的代谢数据，判断在研药物发生药物相互作用的可能性➢ 根据获批药物的真实数据，构建药物的相互作用模型
<p>药代动力学与药效 (PK&Efficacy)</p> <ul style="list-style-type: none">➢ 更详细地评价候选药物的药物动力学参数和性质➢ 为候选药物的筛选，评估与优先性等提供参考➢ 辅助临床前动物模型选择与药效研究➢ 为药物临床试验方案设计提供信息参考➢ 辅助选择更合理的给药方式，并类推到整个药物类型研究中➢ 通过药效数据综合分析，增加候选药物申报的成功机率	<p>药物不良反应追踪与药物注册 (Registration, AERS)</p> <ul style="list-style-type: none">➢ 直观的大数据药物不良反应分析，辅助药物安全评估➢ 分析FDA和EMA审批过程中的差异，为药物审批占得先机。➢ 通过分析药物各阶级详细数据，增加候选药物申报的成功机率

PharmaPendium深度提取FDA,EMA官方文档中的数据

Study type	Study pts.	Sample Size (N)	Design	1 st endpoint	2 nd endpoint	Completion date
Adjuvant	Stage IB, II, III Resected	1160	Double-blind Placebo control	OS	DFS	10/07
Maintenance	Stage III Inoperable	840	Double-blind Placebo control	OS & PFS	-	5/06
First-line	Stage III/IV PS 2-3 LCS <=20 Medical conditions	207	Double-blind BSC control	Symptom improvement	OS TTP	9/06
Refractory	Stage III/IV PS 0-3	624	Double-blind BSC control	OS	PFS Symptoms	9/06
Refractory	Stage III/IV PS 0-2 LCS <=20	207	Double-blind BSC control	Symptom improvement	OS TTP	9/06

BSC=best supportive care; DFS=disease free survival; LCS= Lung cancer subscale; PFS=progression free survival; PS=performance status; OS=overall survival

PharmaPendium深度提取FDA,EMA官方文档中的数据

PharmaPendium®

Browse Search My tools new

Quick Search

All These Sources

靶点
适应症

Drugs
Adverse Effects/Toxicity
Targets
Indications

Search >

Find adverse effect/toxicity data across preclinical, clinical, post-market reports and more

Pharmacokinetic Data
Metabolizing Enz. & Trans. Data
Drug Safety Data
FAERS Data NEW
DDI risk calculator

数千条PK数据规范整理

Pharmacokinetic data search results

21381 records from PK Data: [Sofosbuvir; Velpatasvir (696) OR Interferon Alfacon-1 (8) OR Interferon Alfa-2b, Recombinant (205) OR Sofosbuvir; Velpatasvir; Voxilaprevir (553) OR Peginterferon Alfa-2b; Ribavirin (50) OR Ritonavir (0) OR Ledipasvir; Sofosbuvir (823) OR Telaprevir (1691) OR Simeprevir Sodium (122) OR Elbasvir; Grazoprevir (569) OR Dasabuvir Sodium (27) OR Ribavirin (2818) OR Glecaprevir; Pibrentasvir (465) OR ...

Export date: 10-09-2018

Efficacy Data Search Results For: Drugs: [Gefitinib (684)] AND Phase: [III (684)]

Total results: 684

Sort order: Drug (Ascending); Indication Type (Ascending); Endpoint Type (Ascending);

Preclinical Data Clinical Data All Data

ID	Drug	Species	Study Group	Dose
1	Boceprevir	Human	healthy, Caucasian	400 mg
2	Boceprevir	Rat		3 mg/kg
3	Boceprevir	Human	healthy, Caucasian	1200 mg
4	Boceprevir	Cynomolgus monkey		25 mg/kg

直接查看

规范化数据导出

Drug	Study Number	Phase/Combination	Study Design	Species	Sex	Route	Dose Regimen	Dose Frequency	Endpoint Type	Endpoint Subtype	Endpoint Tested	Value
Gefitinib	IPASS	III	Monotherapy	Human	Both	Oral	250 mg per day		Survival	Progression free survival	Treatment difference in progression-free survival	0.74
Gefitinib	IPASS (D791AC000)	III	Monotherapy	Human	Both	Oral	0		Clinical response	Objective response	Objective response rate in EGFR mutation positive patients	47.3
Gefitinib	IPASS (D791AC000)	III	Monotherapy	Human	Both	Oral	250 mg once daily	Once a day	Clinical response	Complete response	Percentage of patients with complete response	0.8
Gefitinib	IPASS (D791AC000)	III	Monotherapy	Human	Both	Oral	0		Clinical response	Objective response	Objective response rate in mutation unknown group of patients	29.2
Gefitinib	IPASS (D791AC000)	III	Monotherapy	Human	Both	Oral	0		Clinical response	Disease control	Number of patients with disease control	482
Gefitinib	ISEL (D7913C00709)	III	Monotherapy	Human	Both	Oral	250 mg once daily	Once a day	Clinical response	Objective response	Objective response rate in EGFR mutation negative patients	2.6
Gefitinib	ISEL (D7913C00709)	III	Monotherapy	Human	Both	Oral	250 mg once daily	Once a day	Clinical response	Objective response	Objective response rate	10.1
Gefitinib	ISEL	III	Monotherapy	Human	Both	Oral	0		Clinical response	Objective response	Objective response rate	1.6
Gefitinib	IPASS (D791AC000)	III	Monotherapy	Human	Both	Oral	0		Clinical response	Objective response	Objective response rate in EGFR mutation positive patients	47.3
Gefitinib	IPASS (D791AC000)	III	Monotherapy	Human	Both	Oral	0		Clinical response	Response	Number of EGFR mutation negative patients with objective response	20
Gefitinib	IPASS	III	Monotherapy	Human	Both	Oral	250 mg once daily	Once a day	Clinical response	Objective response	Objective response rate	43.0
Gefitinib	ISEL	III	Monotherapy	Human	Both	Oral	250 mg once daily	Once a day	Clinical response	Objective response	Objective response rate	2.6
Gefitinib	ISEL	III	Monotherapy	Human	Both	Oral	0		Clinical response	Objective response	Objective response rate	2.1
Gefitinib	Study 17	III	Combination	Human	Both	Oral	500 mg once daily	Once a day	Clinical response	Objective response	Objective response rate	32.1
Gefitinib	Study 17	III	Combination	Human	Both	Oral	250 mg once daily	Once a day	Clinical response	Objective response	Objective response rate	35.0
Gefitinib	INTEREST;ISEL;IN	III	Monotherapy	Human	Both	Oral	250 mg once daily	Once a day	Clinical response	Response	Number of patients with objective response in patients with EGFR FISH+ tumours	5
Gefitinib	Study 14	III	Combination	Human	Both	Oral	500 mg once daily	Once a day	Clinical response	Objective response	Objective response rate	49.7
Gefitinib	IPASS (D791AC000)	III	Monotherapy	Human	Both	Oral	0		Clinical response	Objective response	Objective response rate in mutation known group of patients	37.9
Gefitinib	IPASS (D791AC000)	III	Monotherapy	Human	Both	Oral	0		Clinical response	Stable disease	Number of patients with stable disease	286
Gefitinib	IPASS	III	Monotherapy	Human	Both	Oral	250 mg once daily	Once a day	Clinical response	Objective response	Objective response rate	43.3



PharmaPendium深度提取FDA,EMA官方文档中的数据

‘原文图片检索’ 功能, 直接原文中的 ‘指定内容’, 便于阅读 ‘关键信息’

PharmaPendium®

Browse Search My tools new

FDA Approval Package - Gefitinib > Medical/Clinical Review

Medical/Clinical Review 021399/S-000 Part 01

clinical review 28/198 Go

2015-06-04 PDF(1305k)
Other Important Information from FDA > Cross Discipline Team Leader Review
206995/S-000 Part 01
... Pharmaceuticals LP September 17, 2014 July 17, 2015 Iressa (Gefitinib)
Clinical Review Primary/ Secondary Reviewer ...

2003-01-31 PDF(2024k)
Medical/Clinical Review > Medical/Clinical Review 021399/S-000 Part 01
... Review(s) **CLINICAL REVIEW** Clinical Review NDA 21-399 Drug Name Medical Reviewer Martin H. Cohen, M.D. ...


2015-06-04 PDF(914k)
Other Important Information from FDA > Cross Discipline Team

Study type	Study pts.	Sample Size (N)	Design	1 ^o endpoint	2 ^o endpoint	Completion date
Adjuvant	Stage IB, II, III Resected	1160	Double-blind Placebo control	OS	DFS	10/07
Maintenance	Stage III Inoperable	840	Double-blind Placebo control	OS & PFS	-	5/06
First-line	Stage III/IV PS 2-3 LCS ≤20 Medical conditions	207	Double-blind BSC control	Symptom improvement	OS TTP	9/06
Refractory	Stage III/IV PS 0-3	624	Double-blind BSC control	OS	PFS Symptoms	9/06
Refractory	Stage III/IV PS 0-2 LCS ≤20	207	Double-blind BSC control	Symptom improvement	OS TTP	9/06

12 of 66

直方图总览，展示副作用分布，辅助决策

多奈哌齐，加兰他敏，卡巴拉汀直方图



PharmaPendium在全球超过100家用户，其中包括FDA，全球前20的制药企业，日本前10的制药企业等



Thank you

